ACW
data caveat$122M3mo
Actinogen Medical
Biotech · Neurology
Xanamem for Alzheimers disease via cortisol modulation
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4C(5mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$6.5M
Dec 2025 4C
Runway
3moCRITICAL
Based on Dec 2025 4C
Market Cap
$122M
Burn Rate
$6.5M/qtr
Dec 2025 4C
Shares Outstanding
3.6B
Pipeline Assets
1
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveRegulatory27 May 2026
Actinogen receives positive scientific advice from EMA
Actinogen Medical received positive scientific advice from the European Medicines Agency (EMA) outlining a clear pathway to marketing approval for Xanamem in Alzheimer's disease, including agreement on regulatory starting materials, design of one additional pivotal Phase 3 trial, and required ancillary studies. The EMA guidance closely aligns with prior FDA guidance, giving Actinogen a defined regulatory pathway in the two largest global pharmaceutical markets.
EMA·Alzheimer's disease·positive
3M Price
ACW.ASX$0.034-10.5% 3M
Low $0.033High $0.048
Pipeline Assets (1)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Capital Raises & Buybacks
12mo dilution 3.6%12mo $17M2 buybacks2 raises
Current shares outstanding: 3.6B
Placement
SPP
Buyback
2026-03-26placement
$0.7M
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
6 transactionsLast 90dNet Buy
Buys6+6 vs prior
Sells0
Buy Value$1267k
warning6 directors bought within 30 days (03-26 – 03-26) — $1267k total
Catalysts (5)· 2 upcoming · 3 past
Xanamem Phase 2 XanaMIA study data
UpcomingExpectedarrow_upwardHigh30 June 2026
SpeculativeremoveMed1 Oct 2026
expand_more3 past catalysts
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High98/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 5 tracked
What drove these scores · rolling 2yr
arrow_drop_up
Stable burn rate — 3% quarterly variation — consistent spend
arrow_drop_up
R&D-focused spend — 90% of opex directed to R&D
Completed catalysts
✓Xanamem (emestedastat) EMA — Actinogen receives positive scientific advice from EMA— Actinogen Medical received positive scientific advice from the European Medicines Agency (EMA) outlining a clear pathway to marketing approval for Xanamem in Alzheimer's disease, including agreement on regulatory starting materials, design of one additional pivotal Phase 3 trial, and required ancillary studies. The EMA guidance closely aligns with prior FDA guidance, giving Actinogen a defined regulatory pathway in the two largest global pharmaceutical markets.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
Ph2/PHASE3Active Not RecruitingEnrollment stale · 789d
XanamemPlacebo
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Dementia Moderate · Dementia, Mild · Alzheimer Disease
RandomizedQuadruple Blind50 Years+
Primary endpoint Effects of 10 mg Xanamem on integrated cognitive and functional abilities
ENROL247
no manual snapshots — enter via record_enrollment.py
Announcements(20)
verified
RegulatoryPSauto_awesome
Actinogen receives positive scientific advice from EMA27 May 2026
expand_more248KB